Official Title
A Phase I Study of ResCure™ to Treat COVID-19 Infection
Brief Summary

This is a Phase I open-label interventional study which will test the efficacy of ResCure™ in the treatment of patients with COVID-19 infection.

Detailed Description

In this Phase I open-label interventional study we will test the efficacy of ResCure™ in the
treatment of patients with COVID-19 infection. Patients being treated will have severe
respiratory symptoms that are at or near requiring the patient be placed on a ventilator.

Status
Withdrawn
Conditions
COVID
COVID-19
Corona Virus Infection
SARS-COV2
Coronavirus-19
SARS Pneumonia
SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere
Interventions

Biological: ResCure™

Patients will be treated with nebulized ResCure™

Eligibility Criteria

Inclusion Criteria:

1. Critically ill patients with SARS from COVID-19 infection on respirators OR

2. Patients with SARS from COVID-19 infection prior or after being placed on respirator

3. Male or female patients 18 years of age and older

Exclusion Criteria:

1. Patients less than 18 years of age

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
United States
Locations

ProgenaBiome
Ventura, California, United States

Investigators

Sabine Hazan, MD, Principal Investigator
ProgenaBiome

Sponsors / Collaborators
Rinati Skin, LLC
NCT Number
NCT04395716
MeSH Terms
Infections
Communicable Diseases
COVID-19
Coronavirus Infections
Severe Acute Respiratory Syndrome